# Trial of Bone-marrow Derived Mesenchymal Stromal Cells (MSC) for New Onset Chronic Lung Allograft Dysfunction

> **NCT02709343** · PHASE2 · COMPLETED · sponsor: **The University of Queensland** · enrollment: 64 (actual)

## Conditions studied

- Chronic Lung Allograft Dysfunction (CLAD)

## Interventions

- **DRUG:** Bone-marrow derived MSCs
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02709343
- **Lead sponsor:** The University of Queensland
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-21
- **Primary completion:** 2023-09-13
- **Final completion:** 2023-10-25
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2023-12-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02709343

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02709343, "Trial of Bone-marrow Derived Mesenchymal Stromal Cells (MSC) for New Onset Chronic Lung Allograft Dysfunction". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02709343. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*